Heron Therapeutics (NASDAQ:HRTX) Q3 Revenue Misses Estimates as CorMedix Asset Deal Lifts Shares
Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
Loading...